27.5 C
Vientiane
Tuesday, September 9, 2025
spot_img
Home Blog Page 420

NYSE Content Advisory: Pre-market update + Accelerant celebrates IPO

NEW YORK, July 25, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-market update + Accelerant celebrates IPO

Ashley Mastronardi delivers the pre-market update on July 25th

  • Stocks are mixed Friday morning after the S&P 500 closed at a record for the 13th time this year. The index has been bolstered by earning season so far with over 80% of quarterly figures topping expectations, according to FactSet.
  • Investors are paying close attention to the relationship between President Trump and Fed Chair Jerome Powell. On Thursday, the President paid a visit to the central bank, ramping up pressure to lower interest rates.
  • Accelerant (NYSE: ARX), a tech-forward platform that helps provide coverage for hard-to-insure companies, will ring the opening bell to celebrate its IPO. Shares surged by 26% during the company’s first day of trade.

Opening Bell
Accelerant (NYSE: ARX) celebrates its initial public offering

Closing Bell
Manchester United (NYSE: MANU) celebrates its pre-season tour of the U.S.

Click here to download the NYSE TV App

 

Nature’s Miracle Holding Inc. (“NMHI”) Management and a Lender Invested $1.69 Million in NMHI Shares through Liability and Debt Conversion

ONTARIO, Calif., July 25, 2025 /PRNewswire/ — Nature’s Miracle Holding Inc. (OTCQB:NMHI) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology today announced that certain members of the Company’s management team including CEO, President and CFO and a Lender agreed to convert a total $1,692,250 in accrued compensation and debt into 12,967,440 shares at a price of $0.1305 per share, which is the Company’s closing stock price on July 24, 2025. 

The Company’s management team converted a total of $1,132,250 in accrued compensation into 8,676,252 shares at $0.1305 per share, including Tie “James” Li, CEO who converted $673,476 into 5,160,739 shares, Zhiyi “Jonathan” Zhang, President who converted $406,691 into 3,116,408 shares and George Yutuc, CFO who converted $52,000 into 399,106 shares. A lender has also agreed to convert  $560,000 of liabilities into 4,291,188 shares. 

James Li, chairman and CEO of Nature’s Miracle commented “We are proud to announce Management and a lender have agreed to the liabilities and debt conversion into the Company’s equity. This will reduce the Company’s liabilities and strengthen our shareholder’s equity. With the recent $100 million distribution deal with Faraday Future and our adoption of up to  $20 million XRP Treasury Program, we are very excited about the future of Nature’s Miracle. We are committed to bring the Company back to Nasdaq or to another qualified National Exchange.”

About Nature’s Miracle Holding Inc.

Nature’s Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing products and services to growers in the Controlled Environment Agriculture (“CEA”) industry in the U.S.  The Company’s Common Stock trades on the OTCQB market (“OTCQB”) under the symbol “NMHI”.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of Nature’s Miracle’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in Nature’s Miracle’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; Nature’s Miracle’s ability to develop and launch new products and services; Nature’s Miracle’s ability to successfully and efficiently integrate future expansion plans and opportunities; Nature’s Miracle’s ability to grow its business in a cost-effective manner; Nature’s Miracle’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of Nature’s Miracle’s business model; developments and projections relating to Nature’s Miracle’s competitors and industry; and Nature’s Miracle’s approach and goals with respect to technology.

These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the quotation of the Company’s shares on the OTC; changes in applicable laws or regulations; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nature’s Miracle’s operates; the risk that Nature’s Miracle’s and its current and future collaborators are unable to successfully develop and commercialize Nature’s Miracle’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that Nature’s Miracle’s is unable to secure or protect its intellectual property; the possibility that Nature’s Miracle’s may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in Nature’s Miracle’s filings from time to time with the SEC.

 

TROOPS, Inc. (NASDAQ: TROO) Intends to Bolster Shareholder Value with Strategic Stock Repurchase

HONG KONG, July 25, 2025 /PRNewswire/ — TROOPS, Inc. (NASDAQ: TROO) (“TROOPS” or the “Company”) today announced that the Company has initiated its stock repurchasing plan by entering into a stock repurchase agreement (the “Stock Repurchase Agreement”) with an existing shareholder (the “Shareholder”).

On July 18, 2025, the Shareholder agreed to the Company’s notice to exercise its repurchase option as outlined in the stock purchase agreement dated on May 28, 2025. On July 22, 2025, the Company entered into the Stock Repurchase Agreement with the Shareholder, pursuant to which the Shareholder agreed to sell, and the Company agreed to repurchase 4,400,000 shares at a purchase price of US$0.90 per share, for a total purchase price of US$3,960,000. The closing of the Stock Repurchase Agreement occurred on July 24, 2025.

This strategic repurchase of 4,400,000 shares of the Company at US$0.90 per share is expected to enhance shareholder value by reducing the number of outstanding shares, potentially increasing earnings per share and strengthening the Company’s capital structure. The transaction underscores the Company’s confidence in its long-term growth prospects and commitment to delivering value to its shareholders.

About TROOPS, Inc.

TROOPS, Inc. is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in (a) money lending business in Hong Kong providing mortgage loans to high quality target borrowers, (b) property investment to generate additional rental income and, (c) the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, big data and blockchain, and cloud computing (SaaS), (d) advisory and referral services in relation to the application of migration, education and visa renewal to its customers, and (e) consultancy services for insurance products in respect of insurance referral to insurance brokers. The group’s vision is to operate as a conglomerate to build synergy within its own sustainable ecosystem thereby creating value to its shareholders.

For more information about TROOPS, Inc., please visit our investor relations website: www.troops.co

Safe Harbor and Informational Statement

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Forward-looking statements in this release include, without limitation, the effectiveness of the Company’s multiple-brand, multiple channel strategy and the transitioning of its product development and sales focus and to a “light-asset” model, Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to have effective internal control over financial reporting; our success in designing and distributing products under brands licensed from others; management of sales trend and client mix; possibility of securing loans and other financing without efficient fixed assets as collaterals; changes in government policy in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in TROOPS’ filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. All information provided in this press release and in the attachments is as of the date of the issuance, and TROOPS does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 25, 2025 /PRNewswire/ — The Kintor Pharmaceutical Limited (the “Company“) is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that:

  • Regarding efficacy, compared to the placebo group, both 0.5% BID (i.e. twice a day) group and 1.0% BID group demonstrated statistically significant therapeutic efficacy and clinical significance. The target area non-vellus hair counts (“TAHC“) of the 0.5% BID group showed an increase of 22.39 hairs/cm2 from baseline, the TAHC of the 1.0% BID group showed an increase of 21.87 hairs/cm2 from baseline, the TAHC of the placebo group showed an increase of 8.73 hairs/cm2 from baseline. The TAHC of the 0.5% BID group showed an increase of 13.66 hairs/cm2 from placebo group, with statistically significant results (P=0.002). The TAHC of the 1.0% BID group showed an increase of 13.14 hairs/cm2 from placebo group, with statistically significant results (P=0.004).
     
    The hair growth assessment (“HGA“) indicators from investigators of 0.5% BID group and 1.0% BID group both experienced significant improvement from placebo group, with a significant therapeutic effect. The results showed that after the treatment of 24 weeks, compared to the placebo group, the HGA indicator of the 0.5% BID group displayed statistically significant results (P=0.000); compared to the placebo group, the HGA indicator of the 1.0% BID group displayed statistically significant results (P=0.013).
     
  • In terms of safety, KX-826 tincture exhibited satisfactory safety and tolerability in the clinical trial, with a low incidence of overall adverse events. No drug-related sexual dysfunction adverse reactions were observed during the entire study period, which indicated an excellent favorable safety profile without observing any new safety signals.

The analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 25, 2025 /PRNewswire/ — The Kintor Pharmaceutical Limited (the “Company“) is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that:

  • Regarding efficacy, compared to the placebo group, both 0.5% BID (i.e. twice a day) group and 1.0% BID group demonstrated statistically significant therapeutic efficacy and clinical significance. The target area non-vellus hair counts (“TAHC“) of the 0.5% BID group showed an increase of 22.39 hairs/cm2 from baseline, the TAHC of the 1.0% BID group showed an increase of 21.87 hairs/cm2 from baseline, the TAHC of the placebo group showed an increase of 8.73 hairs/cm2 from baseline. The TAHC of the 0.5% BID group showed an increase of 13.66 hairs/cm2 from placebo group, with statistically significant results (P=0.002). The TAHC of the 1.0% BID group showed an increase of 13.14 hairs/cm2 from placebo group, with statistically significant results (P=0.004).
     
    The hair growth assessment (“HGA“) indicators from investigators of 0.5% BID group and 1.0% BID group both experienced significant improvement from placebo group, with a significant therapeutic effect. The results showed that after the treatment of 24 weeks, compared to the placebo group, the HGA indicator of the 0.5% BID group displayed statistically significant results (P=0.000); compared to the placebo group, the HGA indicator of the 1.0% BID group displayed statistically significant results (P=0.013).
     
  • In terms of safety, KX-826 tincture exhibited satisfactory safety and tolerability in the clinical trial, with a low incidence of overall adverse events. No drug-related sexual dysfunction adverse reactions were observed during the entire study period, which indicated an excellent favorable safety profile without observing any new safety signals.

The analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.

TROOPS, Inc. (NASDAQ: TROO) Intends to Bolster Shareholder Value with Strategic Stock Repurchase

HONG KONG, July 25, 2025 /PRNewswire/ — TROOPS, Inc. (NASDAQ: TROO) (“TROOPS” or the “Company”) today announced that the Company has initiated its stock repurchasing plan by entering into a stock repurchase agreement (the “Stock Repurchase Agreement”) with an existing shareholder (the “Shareholder”).

On July 18, 2025, the Shareholder agreed to the Company’s notice to exercise its repurchase option as outlined in the stock purchase agreement dated on May 28, 2025. On July 22, 2025, the Company entered into the Stock Repurchase Agreement with the Shareholder, pursuant to which the Shareholder agreed to sell, and the Company agreed to repurchase 4,400,000 shares at a purchase price of US$0.90 per share, for a total purchase price of US$3,960,000. The closing of the Stock Repurchase Agreement occurred on July 24, 2025.

This strategic repurchase of 4,400,000 shares of the Company at US$0.90 per share is expected to enhance shareholder value by reducing the number of outstanding shares, potentially increasing earnings per share and strengthening the Company’s capital structure. The transaction underscores the Company’s confidence in its long-term growth prospects and commitment to delivering value to its shareholders.

About TROOPS, Inc.

TROOPS, Inc. is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in (a) money lending business in Hong Kong providing mortgage loans to high quality target borrowers, (b) property investment to generate additional rental income and, (c) the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, big data and blockchain, and cloud computing (SaaS), (d) advisory and referral services in relation to the application of migration, education and visa renewal to its customers, and (e) consultancy services for insurance products in respect of insurance referral to insurance brokers. The group’s vision is to operate as a conglomerate to build synergy within its own sustainable ecosystem thereby creating value to its shareholders.

For more information about TROOPS, Inc., please visit our investor relations website: www.troops.co

Safe Harbor and Informational Statement

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Forward-looking statements in this release include, without limitation, the effectiveness of the Company’s multiple-brand, multiple channel strategy and the transitioning of its product development and sales focus and to a “light-asset” model, Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to have effective internal control over financial reporting; our success in designing and distributing products under brands licensed from others; management of sales trend and client mix; possibility of securing loans and other financing without efficient fixed assets as collaterals; changes in government policy in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in TROOPS’ filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. All information provided in this press release and in the attachments is as of the date of the issuance, and TROOPS does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

Nature’s Miracle Holding Inc. (“NMHI”) Management and a Lender Invested $1.69 Million in NMHI Shares through Liability and Debt Conversion

ONTARIO, Calif., July 25, 2025 /PRNewswire/ — Nature’s Miracle Holding Inc. (OTCQB:NMHI) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology today announced that certain members of the Company’s management team including CEO, President and CFO and a Lender agreed to convert a total $1,692,250 in accrued compensation and debt into 12,967,440 shares at a price of $0.1305 per share, which is the Company’s closing stock price on July 24, 2025. 

The Company’s management team converted a total of $1,132,250 in accrued compensation into 8,676,252 shares at $0.1305 per share, including Tie “James” Li, CEO who converted $673,476 into 5,160,739 shares, Zhiyi “Jonathan” Zhang, President who converted $406,691 into 3,116,408 shares and George Yutuc, CFO who converted $52,000 into 399,106 shares. A lender has also agreed to convert  $560,000 of liabilities into 4,291,188 shares. 

James Li, chairman and CEO of Nature’s Miracle commented “We are proud to announce Management and a lender have agreed to the liabilities and debt conversion into the Company’s equity. This will reduce the Company’s liabilities and strengthen our shareholder’s equity. With the recent $100 million distribution deal with Faraday Future and our adoption of up to  $20 million XRP Treasury Program, we are very excited about the future of Nature’s Miracle. We are committed to bring the Company back to Nasdaq or to another qualified National Exchange.”

About Nature’s Miracle Holding Inc.

Nature’s Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing products and services to growers in the Controlled Environment Agriculture (“CEA”) industry in the U.S.  The Company’s Common Stock trades on the OTCQB market (“OTCQB”) under the symbol “NMHI”.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of Nature’s Miracle’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in Nature’s Miracle’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; Nature’s Miracle’s ability to develop and launch new products and services; Nature’s Miracle’s ability to successfully and efficiently integrate future expansion plans and opportunities; Nature’s Miracle’s ability to grow its business in a cost-effective manner; Nature’s Miracle’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of Nature’s Miracle’s business model; developments and projections relating to Nature’s Miracle’s competitors and industry; and Nature’s Miracle’s approach and goals with respect to technology.

These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the quotation of the Company’s shares on the OTC; changes in applicable laws or regulations; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nature’s Miracle’s operates; the risk that Nature’s Miracle’s and its current and future collaborators are unable to successfully develop and commercialize Nature’s Miracle’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that Nature’s Miracle’s is unable to secure or protect its intellectual property; the possibility that Nature’s Miracle’s may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in Nature’s Miracle’s filings from time to time with the SEC.

 

Amcor announces registered exchange offers

ZURICH, July 25, 2025 /PRNewswire/ — Amcor plc (“Amcor”) (NYSE: AMCR, ASX: AMC) today announced the commencement of offers (the “exchange offers”) by Amcor Flexibles North America, Inc., Amcor’s wholly-owned subsidiary (the “Issuer”) and the guarantors, including Amcor (the “Guarantors”), to exchange: (1) up to $725,000,000 4.800% Guaranteed Senior Notes due 2028 (the “Old 2028 Notes”) for a like principal amount of 4.800% Guaranteed Senior Notes due 2028, the offer of which has been registered under the Securities Act of 1933, as amended (the “Securities Act”) (the “Exchange 2028 Notes”); (2) up to $725,000,000 5.100% Guaranteed Senior Notes due 2030 (the “Old 2030 Notes”) for a like principal amount of 5.100% Guaranteed Senior Notes due 2030, the offer of which has been registered under the Securities Act (the “Exchange 2030 Notes”); and (3) up to $750,000,000 5.500% Guaranteed Senior Notes due 2035 (the “Old 2035 Notes,” and, together with the Old 2028 Notes and the Old 2030 Notes, the “Old Notes”) for a like principal amount of 5.500% Guaranteed Senior Notes due 2035, the offer of which has been registered under the Securities Act (the “Exchange 2035 Notes,” and, together with the Exchange 2028 Notes and the Exchange 2030 Notes, the “Exchange Notes”).

The terms of the Exchange Notes to be issued in the exchange offers are identical, in all material respects, to the terms of the Old Notes, except that the Exchange Notes will not be subject to restrictions on transfer and the registration rights and additional interest provisions applicable to the Old Notes will not apply to the Exchange Notes. In addition, the Exchange Notes will bear a different CUSIP number than the Old Notes. The purpose of the exchange offers is to satisfy the Issuer’s and the Guarantors’ obligations under the registration rights agreement entered into in connection with the issuance of the Old Notes. None of the Issuer nor any of the Guarantors will receive any proceeds from the exchange offers.

The exchange offers will expire at 5:00 p.m., New York City Time, on August 22, 2025, unless extended. The Exchange Notes will be issued promptly after the expiration of the applicable exchange offer and acceptance of the relevant Old Notes. The terms of the exchange offers and other information relating to the Issuer and the Guarantors and the Exchange Notes are set forth in a prospectus dated July 24, 2025, a copy of which has been filed with the Securities and Exchange Commission. None of the Issuer nor any of the Guarantors has authorized anyone to provide information that is different from the information included in the prospectus.

U.S. Bank Trust Company, National Association has been appointed as exchange agent in connection with the exchange offers of the Old Notes. Questions and requests for assistance or requests for additional copies of the prospectus, or the letter of transmittal, may be directed to the exchange agent addressed as follows:

U.S. Bank Trust Company, National Association

 

By Registered or Certified Mail,
Overnight Delivery:

 

For Information Call:

For Facsimile Transmission

(for Eligible Institutions only):

Corporate Actions

111 Fillmore Ave

St. Paul, MN 55107

Reference: Amcor

Tel. No.: (800) 934-6802

(651) 466-7367

 

Confirm by E-mail:

cts.specfinance@usbank.com

This press release is for informational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security. The exchange offers are being made solely pursuant to the prospectus dated July 24, 2025, including any supplements thereto, and only to such persons and in such jurisdictions as is permitted under applicable law.

About Amcor

Amcor is a global leader in packaging solutions for consumer and healthcare products. With industry-leading innovation capabilities, global scale and technical expertise, we help our customers grow and meet the needs of millions of consumers every day. Our teams develop responsible, more sustainable packaging in flexible and rigid formats across multiple materials. Supported by a commitment to safety, ~70,000 colleagues across ~140 countries bring our global capabilities to local customers and provide local access to global brands. Our work is guided by our purpose of elevating customers, shaping lives and protecting the future.

NYSE: AMCR; ASX: AMC www.amcor.com | LinkedIn | YouTube